Goldshield directors trump rivals’ bid
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Goldshield’s executive directors tabled a £169m bid for the generic drugs group yesterday, trumping an earlier offer from the company’s former boss.
The directors, who are being financed by the buyout group HgCapital, also revealed that they had bought 6.1 million shares in the market at the offer price and had secured acceptances from investors with another 8.7 milllion shares, giving their bid the backing of more than 40 per cent of Goldshield’s shareholders.
The 460p a share cash offer beats a 440p bid made last week by Goldshield’s former chief executive, Ajit Patel, and the Israeli Fuhrer family, which owns another generic pharmaceuticals company, Neopharm.
Goldshield’s independent directors, who are considering both bids, said they would make an announcement in due course, noting that an existing agreement with the Fuhrers and Mr Patel prevent them from recommending a rival bid for five business days.
Shares in Goldshields closed up 0.6 per cent at 471p shortly before the bid was announced to the market last night.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments